V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230000970 | 230000575 | 1.7 | 80.7 | Palliative (P) | 2016-10-28 | 2016-11-04 | Capecitabine + Oxaliplatin 21day | 02 | N | 230028415 | SORAFENIB |
| 230000971 | 230000576 | 1.87 | 82 | Adjuvant (A) | 2015-02-24 | 2015-04-11 | Capecitabine + Oxaliplatin 21day | N | N | 230028464 | VANDETANIB |
| 230000972 | 230000577 | 1.58 | 69 | Adjuvant (A) | 2018-05-04 | 2018-05-11 | Capecitabine + Oxaliplatin 21day | 02 | N | 230028488 | CARBOPLATIN + ETOPOSIDE |
| 230000973 | 230000578 | 1.71 | 78.8 | Adjuvant (A) | 2018-04-14 | 2018-05-14 | Capecitabine 35days + RT | N | N | 230028500 | VANDETANIB |
| 230000974 | 230000579 | 1.7 | 0 | Adjuvant (A) | 2014-10-31 | 2014-11-22 | Temozolomide + RT | N | N | 230028555 | CARBOPLATIN + PACLITAXEL |
| 230000975 | 230000580 | 1.65 | 42.2 | Adjuvant (A) | null | 2015-02-09 | FEC 100 | null | null | 230028563 | FLUOROURACIL + MITOMYCIN + RT |
| 230000976 | 230000581 | 1.54 | 85.7 | Palliative (P) | 2019-12-17 | 2019-12-17 | Capecitabine | N | N | 230000025 | CVP R |
| 230000977 | 230000582 | 1.56 | 69.7 | Palliative (P) | 2018-01-17 | 2018-01-17 | Paclitaxel (2 or 3 weekly) | null | null | 230000027 | CISPLATIN + ETOPOSIDE |
| 230000978 | 230000583 | 1.7 | 63 | Neo-adjuvant (N) | 2016-07-20 | 2016-07-27 | PEMBROLIZUMAB | N | N | 230000314 | CARBOPLATIN + PACLITAXEL |
| 230000979 | 230000584 | null | 70.1 | Palliative (P) | 2017-01-18 | 2017-01-31 | Capecitabine | Y | N | 230000413 | GEFITINIB |
| 230000980 | 230000585 | 1.64 | 70.9 | Adjuvant (A) | 2017-09-04 | 2017-09-04 | CAPECITABINE + OXALIPLATIN | 02 | N | 230000633 | OXALIPLATIN + MDG |
| 230000981 | 230000585 | 1.65 | null | Curative (C) | 2014-09-05 | 2014-09-05 | VANDETANIB | N | null | 230000633 | FLUDARABINE |
| 230000982 | 230000586 | 1.79 | 81 | Palliative (P) | 2016-12-01 | 2016-12-14 | Raltitrexed | 02 | N | 230001447 | SORAFENIB |
| 230000983 | 230000587 | 1.53 | 103.5 | Curative (C) | 2016-01-03 | 2016-01-04 | Oxaliplatin + Modified de Gramont | 02 | N | 230001623 | GEMCARBO |
| 230000984 | 230000587 | 1.6 | 95.5 | null | 2014-08-25 | 2014-09-04 | FLUOROURACIL + MITOMYCIN + RT | N | null | 230001623 | CISPLATIN + GEMCITABINE |
| 230000985 | 230001547 | 1.6 | 56.1 | Neo-adjuvant (N) | 2017-12-08 | 2017-12-29 | Oxaliplatin + Modified de Gramont | N | N | 230001793 | CISPLATIN + VINORELBINE |
| 230000986 | 230000588 | 1.55 | 53 | Palliative (P) | 2013-02-14 | 2015-09-16 | Irinotecan + Modified De Gramont | N | N | 230001957 | GEFITINIB |
| 230000987 | 230000589 | null | 54 | Adjuvant (A) | 2015-04-02 | 2015-04-09 | Bortezomib (weekly) | N | N | 230002017 | ABVD |
| 230000988 | 230000590 | null | 96.2 | null | 2016-04-14 | 2016-04-27 | Oxaliplatin + Modified de Gramont | N | null | 230002211 | TRASTUZUMAB |
| 230000989 | 230000591 | 0 | 45.4 | Disease modification (D) | 2013-05-01 | 2015-03-26 | FEC 60 or 75 | N | N | 230002253 | EOX |
| 230000990 | 230000592 | 1.81 | 86.7 | Neo-adjuvant (N) | 2014-01-01 | 2014-01-07 | LENVATINIB | N | N | 230002366 | CARBOPLATIN + ETOPOSIDE |
| 230000991 | 230000593 | 1.54 | 52 | Neo-adjuvant (N) | 2014-09-05 | 2014-09-08 | Folfirinox | N | N | 230002394 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 230000992 | 230000594 | 1.79 | 77.6 | Adjuvant (A) | 2018-09-15 | 2018-09-19 | GemCarbo Days 1+8 | 2 | N | 230003804 | CAPECITABINE |
| 230000993 | 230000594 | 1.59 | 74 | Curative (C) | 2017-10-02 | 2017-10-10 | Carboplatin + Paclitaxel (3 weekly) | 2 | N | 230003804 | TRASTUZUMAB |
| 230000994 | 230000595 | 0 | 84.6 | Palliative (P) | 2018-12-04 | 2018-12-14 | Sorafenib | N | N | 230004079 | CISPLATIN + DOXORUBICIN |
| 230000995 | 230000596 | 1.5 | 66 | Disease modification (D) | 2017-07-07 | 2017-07-22 | CARBOPLATIN + PACLITAXEL | N | null | 230004152 | SORAFENIB |
| 230000996 | 230000596 | 1.72 | 70.1 | Palliative (P) | 2015-04-26 | 2015-05-09 | Capecitabine + Cisplatin | N | N | 230004152 | PLATO TRIAL |
| 230000997 | 230000597 | 1.54 | 55.4 | Adjuvant (A) | 2017-10-04 | 2017-10-09 | FLUOROURACIL + MITOMYCIN + RT | N | N | 230005042 | CABOZANTINIB |
| 230000998 | 230001272 | null | null | Palliative (P) | 2017-12-03 | 2017-12-10 | CAPECITABINE + OXALIPLATIN | 2 | null | 230005219 | VANDETANIB |
| 230000999 | 230001548 | 1.73 | 92.2 | Adjuvant (A) | 2015-03-23 | 2015-04-07 | Carboplatin + Pemetrexed | N | N | 230005389 | ERLOTINIB |
| 230001000 | 230001548 | 1.68 | 56.6 | Adjuvant (A) | 2018-07-06 | 2018-07-06 | FEC 100 | 02 | N | 230005389 | FCR |
| 230001001 | 230001548 | 1.74 | 88.6 | Adjuvant (A) | 2019-04-17 | 2019-05-02 | Capecitabine + Oxaliplatin 21day | N | N | 230005389 | CARBOPLATIN + PEMETREXED |
| 230001002 | 230001548 | null | 71 | Adjuvant (A) | 2016-04-24 | 2016-05-08 | Temozolomide + RT | N | null | 230005389 | HYDROXYCARBAMIDE |
| 230001003 | 230000598 | 1.68 | 62 | Palliative (P) | 2015-07-19 | 2015-07-19 | Sorafenib | N | N | 230006483 | SORAFENIB |
| 230001004 | 230000598 | 1.64 | 68.3 | Adjuvant (A) | 2018-07-10 | 2018-07-27 | CARBOPLATIN + PACLITAXEL | 02 | N | 230006483 | CAPECITABINE + RT |
| 230001005 | 230000598 | 1.7 | 66.5 | Curative (C) | 2017-02-11 | 2017-02-11 | CAPECITABINE + MITOMYCIN + RT | 02 | N | 230006483 | SORAFENIB |
| 230001006 | 230000598 | 1.67 | 73.5 | Adjuvant (A) | null | 2017-01-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | 99 | N | 230006483 | CAPECITABINE + OXALIPLATIN |
| 230001007 | 230000599 | 1.71 | 77.1 | Disease modification (D) | 2015-01-13 | 2015-01-13 | Capecitabine | N | N | 230008663 | SORAFENIB |
| 230001008 | 230000600 | 1.93 | 83.8 | Palliative (P) | 2017-08-31 | 2017-08-31 | CAPECITABINE + OXALIPLATIN | N | N | 230008741 | CARBOPLATIN + ETOPOSIDE |
| 230001009 | 230000600 | 1.67 | 73 | Adjuvant (A) | 2016-08-20 | 2016-09-06 | Bendamustine+Rituximab (1st Course) | 2 | N | 230008741 | RITUXIMAB |
| 230001010 | 230000600 | 1.68 | 60 | Adjuvant (A) | 2015-03-23 | 2015-03-26 | CHOP R - 21 days | 02 | N | 230008741 | CARBOPLATIN + PEMETREXED |
| 230001011 | 230001676 | 1.61 | 58 | Adjuvant (A) | 2015-12-15 | 2015-12-21 | Trastuzumab Subcutaneous | 02 | N | 230009376 | CISPLATIN + GEMCITABINE |
| 230001012 | 230000601 | null | 74.4 | Adjuvant (A) | 2019-03-20 | 2019-03-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 230009748 | CARBOPLATIN + PACLITAXEL |
| 230001013 | 230000602 | 1.87 | 92.4 | Palliative (P) | 2017-04-26 | 2017-04-27 | Oxaliplatin + Modified de Gramont | 02 | N | 230009793 | SORAFENIB |
| 230001014 | 230000603 | 1.53 | null | Palliative (P) | 2016-04-05 | 2016-04-05 | Sorafenib | N | null | 230009824 | IRINOTECAN + MDG |
| 230001015 | 230000604 | 1.72 | 50.15 | Adjuvant (A) | 2017-03-18 | 2017-03-23 | Capecitabine 35days + RT | 2 | Y | 230009975 | IMATINIB |
| 230001016 | 230000605 | 1.59 | 85.8 | Adjuvant (A) | 2014-08-10 | 2014-11-30 | ESPAC-4 TRIAL | N | N | 230011679 | CAPECITABINE + GEMCITABINE |
| 230001017 | 230000605 | null | 74.4 | null | 2018-04-02 | 2018-04-28 | Capecitabine | N | null | 230011679 | VANDETANIB |
| 230001018 | 230000605 | 1.79 | null | Palliative (P) | 2016-12-22 | 2016-12-25 | Capecitabine (21 day) + Irinotecan | N | N | 230011679 | CAPECITABINE |
| 230001019 | 230000606 | 1.56 | 97 | Adjuvant (A) | 2017-02-14 | 2017-02-14 | Doxorubicin 75mg/m2 | N | N | 230012318 | RUXOLITINIB |